Daily Morning Note – 2 June 2021


Asian stocks look set for a steady open Wednesday after U.S. equities inched lower as the tussle between economic optimism and inflation concern continues to play out in markets. Treasury yields edged up.

Futures rose modestly in Japan and Australia but dipped in Hong Kong. The S&P 500 and Nasdaq 100 closed with small losses after U.S. manufacturing data topped estimates but also signaled supply shortages and labor constraints. U.S. equity contracts slipped.


SG News

Ascott Trust (ART) will acquire three rental housing properties in Japan for 6.78 billion yen (S$85.2 million), it said on Tuesday. The properties – City Court Kita 1 jo, Big Palace Minami 5 jo and Alpha Square Kita 15 jo – have a total of 411 units and are located in central Sapporo. Their average Ebitda (earnings before interest, tax, depreciation and amortisation) yield is about 4 per cent, the stapled hospitality group added.

Mapletree NAC Trust’s (MNACT) trustee on May 31 priced S$250 million of perpetual securities at a distribution rate of 3.5 per cent to yield 252.7 basis points over the five-year swap offer rate. The perps, MNACT’s first, were sold at par and may be called by the issuer after five years, DBS, as trustee, said on Tuesday. Swap transactions will be entered into to swap the Singapore dollar distribution rate into Japanese yen fixed interest rate, the trust’s manager said.

Top Glove‘s plan to list in Hong Kong to raise up to US$1 billion has been delayed as the world’s largest rubber glove maker seeks to resolve a US import ban on its products, sources with direct knowledge of the matter said. The Malaysian firm, which is already listed in Kuala Lumpur and Singapore, flagged in late April it would sell 793.5 million shares in the listing, half what the company proposed in its application to the Hong Kong Stock Exchange in February. However, the deal has stalled as the company awaits indications from US Customs and Border Protection on whether an imports ban would be lifted any time soon, the sources said.

Raffles Medical has partnered a subsidiary of China Life Insurance (Group) to boost collaborations in China’s healthcare market, as part of its continued expansion there. In a joint statement on Tuesday, the group said it has signed a memorandum of understanding with China Life Healthcare Investment Company (CLHI), a healthcare investment platform and service provider. Both parties will look at initiatives across several areas, including collaborations in the provision of medical services, healthcare management, training and development as well as healthcare financing through insurance, with a focus on supporting ageing populations.

US News

The price of Tesla vehicles is increasing due to supply chain pressures across the auto industry, particularly for raw materials, Elon Musk said on Monday in response to a tweet. “Prices increasing due to major supply chain price pressure industry-wide. Raw materials especially,” Mr Musk said in a tweet.

Johnson & Johnson must pay a US$2.1 billion award to women who claimed its baby powder was contaminated with cancer-causing asbestos, after the US Supreme Court left intact the largest verdict in the almost decade-long litigation over the iconic product. The top US court without comment on Tuesday refused to consider J&J’s objections to a St Louis jury’s 2018 finding that its talc-based powder helped cause ovarian cancer in 20 women.

Gold prices rose to a near five-month high on Tuesday, boosted by a weaker dollar and growing inflationary pressures, while investors awaited more US data to gauge the extent of global economic recovery. Spot gold was up 0.2 per cent at US$1,911.45 per ounce by 2.55am GMT, after hitting its highest since Jan 8 at US$1,914.26 earlier in the session. US gold futures rose 0.5 per cent to US$1,914.20 per ounce.

US manufacturing expanded at a faster pace in May, propelled by stronger orders growth that underscores sustained, robust demand. A measure of factory activity rose to 61.2 from 60.7 a month earlier, according to data released Tuesday by the Institute for Supply Management. Readings above 50 indicate expansion, and the May figure was about in line with projections. The report also showed still-elevated input prices and a fresh high in order backlogs. The increase in the group’s gauge of new orders – just below a more than 17-year high – and the longest delivery times since 1974 indicate manufacturers continue to struggle with supply shortages, shipping delays and difficulty finding skilled labour.

Source: SGX Masnet, The Business Times, Bloomberg, Channel NewsAsia, Reuters, CNBC, PSR


Alibaba Health Information Technology Ltd

Analyst: Chua Wei Ren

Recommended Action: Technical BUY

Alibaba Health Information Technology Ltd (HKEX: 241) technical is set to rally in the short-term

Buy spot: 19.72 Stop loss: 18.12 Take profit 1: 21.80 Take profit 2: 25.00

>> Read more technical reports

HK Reports – Read up on our Hong Kong reports here

Webinar Of The Week

Market Outlook: Weekly Market Outlook: Sembcorp, Singtel, Frasers Centrepoint Trust, SG REITs Monthly, SG Weekly

Date: 31 May 2021

For more on Market Outlook

Updates summarised in 3 minutes

Phillip Research in 3 minutes: #29 – Keppel Corporation; Initiation

For more videos on Phillip in 3 Mins

Read the research report(s), available through the link(s) above, for complete information including important disclosures Important Information

The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided 揳s is?without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.
Confidentiality Note
This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.


Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you


This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  


Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com